Proposals to improve adherence to immunomodulatory therapies in patients with multiple sclerosis

Proposals to improve adherence to immunomodulatory therapies in patients with multiple sclerosis

Introduction: The objective of this work was to assess the factors identified in the Global Adherence Project (GAP) in disease-modifying therapy (DMT) in patients with multiple sclerosis (MS) and to propose measures directed at improving adherence. It was proposed to prepare questionnaires to detect...

Full description

Bibliographic Details
Main Authors:	E. Arroyo, M. González, C. Grau, C. Arnal, M. Bujanda, P. de Castro, L. Grau, M. Martínez, C. Ramo, V. Sánchez, O. Sánchez-Soliño
Format:	Article
Language:	English
Published:	Elsevier España 2010-01-01
Series:	Neurología (English Edition)
Online Access:	http://www.sciencedirect.com/science/article/pii/S2173580820701021

Similar Items

Global Adherence Project to Disease-Modifying Therapies in Patients With Relapsing Multiple Sclerosis: 2-Year Interim Results
by: E. Arroyo, et al.
Published: (2010-01-01)

Herramientas para mejorar la adherencia al tratamiento con inmunomoduladores en pacientes con esclerosis múltiple
by: E. Arroyo, et al.
Published: (2010-11-01)

Estudio global de adherencia a los tratamientos inmunomoduladores en pacientes con esclerosis múltiple remitente recidivante: resultados a 2 años
by: E. Arroyo, et al.
Published: (2010-09-01)

Analysis of the pain in multiple sclerosis patients
by: L. Grau-López, et al.
Published: (2011-01-01)

Role of microglia in the pathogenesis of multiple sclerosis and links to immunomodulatory therapy
by: P. Valiukevičius, et al.
Published: (2023-10-01)

Adherence to immunomodulatory drugs in patients with multiple myeloma.
by: Amélie Cransac, et al.
Published: (2019-01-01)

Predictors of adherence and persistence to disease-modifying therapies in Multiple Sclerosis
by: Gisela Zanga, et al.
Published: (2021-10-01)

Análisis del dolor en pacientes con esclerosis múltiple
by: L. Grau-López, et al.
Published: (2011-05-01)

Adherence to disease modifying therapies in patients with multiple sclerosis
by: D. Pileckė, et al.
Published: (2019-06-01)

Adherence to disease-modifying therapies in patients with multiple sclerosis
by: Kołtuniuk A, et al.
Published: (2018-08-01)

A comparative study of melatonin and immunomodulatory therapy with interferon beta and glatiramer acetate in a mouse model of multiple sclerosis
by: E.J. Ramos González, et al.
Published: (2021-05-01)

The immunomodulatory phenomenon of vitamin D in the pathogenesis of Multiple Sclerosis
by: Karolina Raksa, et al.
Published: (2023-03-01)

Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis
by: Alosaimi FD, et al.
Published: (2017-03-01)

Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence
by: Francesco Patti
Published: (2010-01-01)

Patient choice and adherence with disease-modifying therapy in multiple sclerosis
by: Burke, G, et al.
Published: (2004)

Longitudinal Serum Neurofilament Levels of Multiple Sclerosis Patients Before and After Treatment with First-Line Immunomodulatory Therapies
by: André Huss, et al.
Published: (2020-08-01)

Characterization of recent thymic emigrants (RTEs), transitional B and Th17 cells in multiple sclerosis (MS)
by: Teniente-Serra Aina, et al.
Published: (2011-11-01)

Factors Associated with Therapeutic Adherence in Multiple Sclerosis in Spain
by: Soria C, et al.
Published: (2023-03-01)

Immunomodulatory Potential of Human Mesenchymal Stem Cells and their Exosomes on Multiple Sclerosis
by: Hussein Baharlooi, et al.
Published: (2022-03-01)

Regulatory role of vitamin D in T-cell reactivity against myelin peptides in relapsing-remitting multiple sclerosis patients
by: Grau-López Laia, et al.
Published: (2012-09-01)

Tolerogenic Dendritic Cells as a Promising Antigen-Specific Therapy in the Treatment of Multiple Sclerosis and Neuromyelitis Optica From Preclinical to Clinical Trials
by: Georgina Flórez-Grau, et al.
Published: (2018-05-01)

The Impact of Adherence to Disease-Modifying Therapies on Functional Outcomes in Veterans with Multiple Sclerosis
by: Meheroz H Rabadi, et al.
Published: (2021-07-01)

Adherence to Anticholinergic Therapy and Clean Intermittent Self-Catheterization in Patients With Multiple Sclerosis
by: Damien Motavasseli, et al.
Published: (2018-06-01)

A Cochrane review on immunomodulatory treatments in clinically isolated syndromes at risk of converting to multiple sclerosis
by: Clerico, M, et al.
Published: (2006)

Symptomatic therapy in multiple sclerosis
by: Teresa C. Frohman, et al.
Published: (2011-03-01)

Transcriptomics identifies blunted immunomodulatory effects of vitamin D in people with multiple sclerosis
by: Wei Z. Yeh, et al.
Published: (2024-01-01)

Immunomodulatory treatment in multiple sclerosis: experience at a Brazilian center with 390 patients
by: Charles Peter Tilbery, et al.
Published: (2006-03-01)

Treatment adherence in multiple sclerosis: a survey of Belgian neurologists
by: Decoo D, et al.
Published: (2015-11-01)

Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
by: Morillo Verdugo R, et al.
Published: (2019-02-01)

Plasma protein profiling reveals dynamic immunomodulatory changes in multiple sclerosis patients during pregnancy
by: Georgia Papapavlou Lingehed, et al.
Published: (2022-07-01)

Bridging Therapies With Injectable Immunomodulatory Drugs in the Management of Multiple Sclerosis: A Delphi Survey of an Italian Expert Panel of Neurologists
by: Girolama Alessandra Marfia, et al.
Published: (2022-07-01)

Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird’s Eye View
by: Elizabeth A. Mills, et al.
Published: (2018-02-01)

Therapy satisfaction and adherence in patients with relapsing–remitting multiple sclerosis: the THEPA-MS survey
by: Rocco Haase, et al.
Published: (2016-07-01)

Nursing Care of Patients with Multiple Sclerosis During Immunomodulatory Treatment of First-line Drugs
by: Maria Wilkiewicz, et al.
Published: (2013-06-01)

Pathogenetic therapy of multiple sclerosis
by: N. V. Komissarova, et al.
Published: (2023-09-01)

Combined Therapy of Vitamin D3-Tolerogenic Dendritic Cells and Interferon-β in a Preclinical Model of Multiple Sclerosis
by: Bibiana Quirant-Sánchez, et al.
Published: (2021-11-01)

Immunomodulatory treatments for preventing conversion from clinically isolated syndromes to multiple sclerosis: a Cochrane review on their efficacy
by: Clerico, M, et al.
Published: (2007)

Ependymal cells and multiple sclerosis: proposing a relationship
by: Dale Hatrock, et al.
Published: (2020-01-01)

Follow-up investigation of 12 proposed linkage regions in multiple sclerosis.
by: Herrera, B, et al.
Published: (2006)

Cost-effectiveness of four immunomodulatory therapies for relapsingremitting multiple sclerosis: A Markov model based on data a Balkan country in socioeconomic transition
by: Janković Slobodan M., et al.
Published: (2009-01-01)